Gavocabtagene autoleucel

加沃妥基奥仑赛

Report date: 2024/01/02 20:03:52

Base Information

Drug NameGavocabtagene autoleucel

Drug Alias Namegavo-celTC-210

ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > Autologous

Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsAnti-Mesothelin

TargetsMesothelin

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsCholangiocarcinoma +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesTcr2 Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb Srlcompany Tcr2 Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsCholangiocarcinoma +[4]

Inactive IndicationsN/A

Other Information

ATC CodeN/A